<DOC>
	<DOCNO>NCT01147900</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity , safety reactogenicity dTpa ( Boostrix™ vaccine ) booster dose give 10 year previous vaccination dTpa GSK 263855/029 study . Only subject part primary study invite participate study.This protocol post deal objective &amp; outcome measure booster phase . The objective &amp; outcome measure primary phase present separate study ( see reference ) .</brief_summary>
	<brief_title>Evaluation Boostrix™10 Years After Previous Booster Vaccination</brief_title>
	<detailed_description>All subject receive booster dose vaccine receive primary study . Subjects receive investigational vaccine formulation , receive Boostrix™ present study .</detailed_description>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . Male female subject receive Boostrix™ , Boostrix™US formulation investigational vaccine formulation study 263855/029 . Written inform consent obtain subject . Additional criterion check booster vaccination . Healthy subject establish medical history clinical examination . Female subject nonchildbearing potential may receive booster vaccine . Female subject childbearing potential may receive booster vaccine , subject : practices/has practice adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire booster epoch . Exclusion criterion check study entry : Previous booster vaccination diphtheria , tetanus , pertussis since dose receive study 263855/029 . History diphtheria , tetanus , laboratory confirm pertussis disease . Any confirm suspected immunosuppressive immunodeficiency condition , base medical history physical examination . History reaction hypersensitivity likely exacerbate component vaccine . Occurrence transient thrombocytopenia neurological complication follow early immunisation diphtheria and/or tetanus . Occurrence follow adverse event previous administration DTP vaccine : hypersensitivity reaction component vaccine , encephalopathy unknown aetiology occur within seven day follow previous vaccination pertussiscontaining vaccine , fever &gt; = 40 °C ( axillary temperature ) within 48 hour vaccination due another identifiable cause , collapse shocklike state within 48 hour vaccination , convulsion without fever , occur within three day vaccination . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Additional exclusion criterion check subject booster vaccination administration : Use investigational nonregistered product study vaccine ( ) within 30 day precede booster dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior booster dose . Administration vaccine foreseen study protocol within 30 day prior booster vaccination , plan administration active study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Administration immunoglobulins and/or blood product within three month precede booster dose plan administration study period . Acute disease and/or fever time enrolment . Fever define temperature ≥ 37.5°C oral , axillary tympanic setting . Subjects minor illness without fever may enrol discretion investigator . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>28 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Immune persistence</keyword>
	<keyword>Boostrix</keyword>
	<keyword>dTpa booster study</keyword>
</DOC>